Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mini-oral Pulse Steroid with NCES for Resistant Vitiligo
NCT06974669Not yet recruiting
- Sponsor
- Cairo University
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dexamethasone in Vitiligo (2 arms), sponsored by Cairo University. Primary endpoints: Percent change in pigmentation at 3 months and Percent change in surface area at 3 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
dexamethasone
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06974669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974669.